Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024.
Related news for (BIOR)
- biora therapeutics announces $3 million registered direct offering priced at-the-market under nasdaq rules
- biora therapeutics shares progress on smaller biojet™ clinical device with largest payload of any ingestible injectable at the 14th annual podd meeting
- biora therapeutics to reveal 00-size biojet™ device at the 14th annual partnership opportunities in drug delivery meeting
- biora therapeutics to present at the 19th annual peptide therapeutics symposium
- biora therapeutics announces award-winning abstract to be presented at american college of gastroenterology annual scientific meeting 2024